Ali-Jackson Kamil
Known title: Chief Legal OfficerCIK: 0001654337
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ACRS Not Highlighted in Recent Pre‑Market Moves. In the past week, pre‑market activity focused on large financial names and a list of 20 stocks, but Aclaris Therapeutics was not mentioned. The moves in big banks and other sectors could influence overall market sentiment, which may affect smaller biotech names like ACRS. No direct company news was reported, so the impact is limited at this time.
Transaction History
| RIGL | ▼ Sell | Open Market | 2,500 | $88K | 6/22/2026 | View on chart |
| RIGL | ▼ Sell | Open Market | 2,500 | $73K | 5/26/2026 | View on chart |
| RIGL | ▲ Buy | Grant | 5,750 | $0 | 5/15/2026 | View on chart |
| RIGL | ▲ Buy | Grant | 2,500 | $0 | 5/23/2025 | View on chart |
| RIGL | ▲ Buy | Grant | 25,000 | $0 | 5/25/2024 | View on chart |
| RIGL | ▲ Buy | Grant | 25,000 | $0 | 5/26/2023 | View on chart |
| RIGL | ▲ Buy | Grant | 18,750 | $0 | 5/20/2022 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 3,875 | — | 1/3/2022 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 27,905 | — | 1/3/2022 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 6,638 | — | 1/3/2022 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 7,100 | — | 1/3/2022 | View on chart |
| ACRS | ▼ Sell | Gift | 7,500 | $0 | 3/11/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RIGL: No Recent Company-Specific News Identified
Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.
RIGL: No Recent Company-Specific News Identified. Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.